After mild traumatic brain injury (TBI), a molecule called complement factor C1q may play a role in the secondary effects of brain injury, such as sleep disruption, epileptic activity, and ...

Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a detailed analysis.

Investigators working at Gladstone Institutes reported new insights into sleep disturbances and seizures that can be a late consequence of even mild traumatic brain injuries (TBI), and how we may one ...

Pembrolizumab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences, a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated ...